Evidence mapPaperPMID 37899757Full record

ArticleJournal of cachexia, sarcopenia and muscle2023

D3-creatine dilution, computed tomography and dual-energy X-ray absorptiometry for assessing myopenia and physical function in colon cancer: A cross-sectional study.

En Cheng, Bette J Caan, Peggy M Cawthon, William J Evans, Marc K Hellerstein, Mahalakshmi Shankaran, Kristin L Campbell, Alexandra M Binder, Barbara Sternfeld, Jeffrey A Meyerhardt and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

En ChengDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0001-9523-9310
Bette J CaanDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Peggy M CawthonSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California, USA.
William J EvansDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, California, USA.
Marc K HellersteinDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, California, USA.
Mahalakshmi ShankaranDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, California, USA.
Kristin L CampbellDepartment of Physical Therapy, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Alexandra M BinderPopulation Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Barbara SternfeldDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kathryn H SchmitzDivision of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Elizabeth M Cespedes FelicianoDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.ORCID 0000-0003-1192-4017
Kaiser Permanente · USUniversity of California, Berkeley · USAlbert Einstein College of Medicine · USDana-Farber Cancer Institute · USDuke Medical Center · USUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Hawaiʻi at Mānoa · USUniversity of Pittsburgh · US

Funding

Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training InterventionR37CA263064 · UNIVERSITY OF HAWAII AT MANOA · 2025 to 2025
$627k
D3-creatine dilution to determine skeletal muscle mass in colon cancer patientsR01CA240394 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI Elizabeth Marjorie Cespedes Feliciano · 2022 to 2022
$379k
NCI NIH HHS R01 CA206196NCI NIH HHS R01 CA240394NCI NIH HHS R37 CA263064
6 · The paper itself

Abstract

backgroundLow skeletal muscle mass (myopenia) is common in cancer populations and is associated with functional decline and mortality, but prior oncology studies did not assess total body skeletal muscle mass. Instead, they measured surrogates such as cross-sectional area (CSA) of skeletal muscle at L3 from computed tomography (CT) or appendicular lean mass (ALM) from dual-energy X-ray absorptiometry (DXA). D3-creatine (D3Cr) dilution is a non-invasive method to assess total body skeletal muscle mass, which has been examined in a variety of populations but not in cancer. To compare the associations of D3Cr muscle mass, CT CSA, and DXA ALM with myopenia and physical function, we conducted a cross-sectional study among 119 patients with colon cancer (2018-2022).

methodsFor each technique (D3Cr, CT and DXA), myopenia was defined as the lowest sex-specific quartile of its measurement. Physical function was measured by the short physical performance battery and grip strength. We calculated Pearson correlations (r) among three techniques, computed Cohen's kappa coefficients (κ) to assess the agreement of myopenia, and estimated Pearson correlations (r) of three techniques with physical function. All analyses were sex-specific.

resultsSixty-one (51.3%) participants were male, the mean (standard deviation) age was 56.6 (12.9) years, and most (68.9%) had high physical function (short physical performance battery: ≥11 points). Correlations and myopenia agreement among three techniques were greater in men than women; for example, regarding D3Cr muscle mass versus CT CSA, r was 0.73 (P < 0.001) for men versus 0.45 (P < 0.001) for women, and κ was 0.82 (95% CI: 0.65, 0.99) for men versus 0.24 (95% CI: -0.08, 0.52) for women. Among men, higher D3Cr muscle mass was significantly correlated with faster gait speed (r = 0.43, P < 0.01) and stronger grip strength (r = 0.32, P < 0.05); similar correlations were observed for CT CSA and DXA ALM. However, among women, no measure of muscle or lean mass was significantly associated with physical function.

conclusionsThis is the first study using D3-creatine dilution method to assess muscle mass in a cancer population. Regardless of the techniques used for muscle or lean mass assessment, we observed stronger correlations, greater myopenia agreement, and more significant associations with physical function in men with colon cancer than women. D3Cr, CT and DXA are not interchangeable methods for assessing myopenia and physical function, especially in women with colon cancer. Future studies should consider relative advantages of these techniques and examine the D3-creatine dilution method in other cancer types.

Indexed as

Colonic NeoplasmsCreatineAbsorptiometry, PhotonCross-Sectional StudiesFemaleHumansMaleMiddle AgedMuscular AtrophyTomography, X-Ray ComputedCreatineComputed tomographyD3-CreatineDual-energy X-ray absorptiometryMusclePhysical performanceSexX-ray

Identifiers

PMID37899757
PMCPMC10751410
OpenAlexW4388014344

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.